Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified

American Journal of Surgical Pathology

Volumn 29, Issue 10, 2005, Pages 1284-1293

  Asano, Naoko ^a,b   Suzuki, Ritsuro ^a   Kagami, Yoshitoyo ^a   Ishida, Fumihiro ^b   Kitamura, Kunio ^c   Fukutani, Hisashi ^d   Morishima, Yasuo ^a   Takeuchi, Kengo ^e   Nakamura, Shigeo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Ichinomiya Municipal Hospital   (Japan)

^d AICHI PREFECTURAL UNIVERSITY   (Japan)

^e CANCER INSTITUTE   (Japan)

Author keywords

Cytotoxic molecule; Immunohistopathology; Peripheral T cell lymphoma; Prognosis; Unspecified (PTCL U)

Indexed keywords

ANTHRACYCLINE; CD15 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC FACTOR; GRANZYME B; LACTATE DEHYDROGENASE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW METASTASIS; CANCER REGRESSION; CANCER SURVIVAL; CELL GRANULE; CLINICAL FEATURE; CORRELATION ANALYSIS; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONSET AGE; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SCORING SYSTEM; SEX DIFFERENCE; SYMPTOM; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLOW CYTOMETRY; GRANZYMES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCLUSION BODIES; LYMPH NODES; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PROGNOSIS; RNA-BINDING PROTEINS; SERINE ENDOPEPTIDASES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 25444476081     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000173238.17331.6b     Document Type: Article

References (65)

1. Anderson JR, Armitage JO, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol. 1998;9:717-720.
2. Anderson P, Nagler-Anderson C, O'Brien C, et al. A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J Immunol. 1990;144:574-582.
3. Ansell SM, Habermann TM, Kurtin PJ, et al. Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma. J Clin Oncol. 1997;15:2296-2301.
4. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol. 1998;16:2780-2795.
5. Arnulf B, Copie-Bergman C, Delfau-Larue M-H, et al. Nonhepatosplenic γδ T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood. 1998;91:1723-1731.
6. Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma. 2003;44:241-249.
7. Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas: clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol. 1997;8:583-592.
8. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol. 2003;27:1513-1522.
9. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102:2213-2219.
10. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102:4261-4269.
11. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483-492.
12. Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104:3358-3360.
13. Boulland ML, Kanavaros P, Wechsler J, et al. Cytotoxic protein expression in natural killer cell lymphomas and in αβ and γδ peripheral T-cell lymphomas. J Pathol. 1997;183:432-439.
14. Brousset P, Butet V, Chittal S, et al. Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody. Lab Invest. 1992;67:457-464.
15. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501-4513.
16. Chiang AK, Chan AC, Srivastava G, et al. Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int J Cancer. 1997;73:332-338.
17. - T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol. 1998;153:1483-1490.
18. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood. 1996;88:4265-4274.
19. Daum S, Foss HD, Anagnostopoulos I, et al. Expression of cytotoxic molecules in intestinal T-cell lymphomas: the German Study Group on Intestinal Non-Hodgkin Lymphoma. J Pathol. 1997;182:311-317.
20. De Bruin PC, Kummer JA, Van der Valk P, et al. Granzyme B expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. Blood. 1994;84:3785-3791.
21. Dukers DF, ten Berge RL, Oudejans JJ, et al. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. J Clin Pathol. 1999;52:129-136.
22. Emile JF, Boulland ML, Haioun C, et al. CD5- CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood. 1996;87:1466-1473.
23. Felgar RE, Macon WR, Kinney MC, et al. TIA-1 expression in lymphoid neoplasms: identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol. 1997;150:1893-1900.
24. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996;88:4005-4011.
25. Froelich CJ, Dixit VM, Yang X. Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases. Immunol Today. 1998;19:30-36.
26. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474-2479.
27. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood. 1998;92:76-82.
28. Griffiths GM, Mueller C. Expression of perform and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells. Immunol Today. 1991;12:415-419.
29. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma Study Group. Blood. 1994;84:1361-1392.
30. Henkart PA. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity. 1994;1:343-346.
31. Ichimura K, Kagami Y, Suzuki R, et al. Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical states. Pathol Int. 2003;53:333-344.
32. Jaffe ES. Pathologic and clinical spectrum of post-thymic T-cell malignancies. Cancer Invest. 1984;2:413-426.
33. Jaffe ES, Harris NL, Stein H, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours. Lyon, France: IARC Press, 2001.
34. Jaffe ES, Krenacs L, Raffeld M. Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann Oncol. 1997;8(suppl 2):17-24.
35. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003;40:175-184.
36. Kagami Y, Suzuki R, Taji H, et al. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients. Am J Surg Pathol. 1999;23:1184-1200.
37. Kamarashev J, Burg G, Mingari MC, et al. Differential expression of cytotoxic molecules and killer cell inhibitory receptors in CD8+ and CD56+ cutaneous lymphomas. Am J Pathol. 2001;158:1593-1598.
38. Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the revised European-American lymphoma (REAL) classification. Eur J Cancer. 2002;38:75-81.
39. Kluin PM, Feller A, Gaulard P, et al. Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology. Histopathology. 2001;38:250-270.
40. Ko YH, Kim CW, Park CS, et al. Revised European-American lymphoma: REAL classification of malignant lymphomas in the Republic of Korea. Cancer. 1998;83:806-812.
41. Krenacs L, Smyth MJ, Bagdi E, et al. The serine protease granzyme M is preferentially expressed in NK-cell, γδ T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood. 2003;101:3590-3593.
42. Krenacs L, Wellmann A, Sorbara L, et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood. 1997;89:980-989.
43. Kumar S, Krenacs L, Medeiros J, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T-lymphocytes. Hum Pathol. 1998;29:397-403.
44. López-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol. 1998;9:849-855.
45. Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50:696-702.
46. Macon WR, Levy NB, Kurtin PJ, et al. Hepatosplenic αβ T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic γδ T-cell lymphomas. Am J Surg Pathol. 2001;25:285-296.
47. Moller MB, Gerdes AM, Skjodt K, et al. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:1085-1091.
48. Montalbán C, Obeso G, Gallego A, et al. Peripheral T-cell lymphoma: a clinicopathological study of 41 cases and evaluation of the prognostic significance of the updated Kiel classification. Histopathology. 1993;22:303-310.
49. NPM/ALK expression. Am J Surg Pathol 1997;21:1420-1432.
50. Niitsu N, Nakamine H, Okamoto M, et al. Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. Br J Haematol. 2003;123:621-630.
51. Pescarmona E, Pignoloni P, Puopolo M, et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol. 2001;195:361-366.
52. Pinkus GS, Said JW. Peripheral T-cell lymphomas. In: Daniel MK, ed. Neoplastic Hematopathology. Baltimore: Williams & Wilkins, 2001:1091-1164.
53. Ralfkaier E, Wollf-Sneedorff A, Thomsen K, et al. T-cell receptor gamma delta-positive peripheral T-cell lymphomas presenting in the skin: a clinical, histological and immunophenotypic study. Exp Dermatol. 1992;1:31-36.
54. Rüdiger T, Weisenburger DD, Anderson JR, et al. Non-Hodgkin's Lymphoma Classification Project. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13:140-149.
55. Salhany KE, Feldman M, Kahn MJ, et al. Hepatosplenic gammadelta T-cell lymphoma: ultrastractural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. Hum Pathol. 1997;28:674-685.
56. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998;22:881-893.
57. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas: report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003;97:610-627.
58. Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today. 1995;16:202-206.
59. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96:2993-3000.
60. Suzumiya J, Takeshita M, Kimura N, et al. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood. 1994;83:2255-2260.
61. Tian Q, Streuli M, Saito H, et al. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell. 1991;67:629-639.
62. Toro JR, Beaty M, Sorbara L, et al. γδ T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol. 2000;136:1024-1032.
63. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101:3407-3412.
64. Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2 and activated T-cell marker, and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma and ATLL. Blood. 2004;103:236-241.
65. Yamashita Y, Yatabe Y, Tsuzuki T, et al. Perform and granzyme expression in cytotoxic T-cell lymphomas. Mod Pathol. 1998;11:313-323.